Dr. David Marks, M.D.
What this data tells you about Dr. Marks
Dr. David Marks is a pulmonary disease in San Antonio, TX, with 19 years in practice. Based on federal Medicare data, Dr. Marks performed 5,088 Medicare services across 3,185 unique beneficiaries.
Between the years covered by Open Payments, Dr. Marks received a total of $367,544 from 58 pharmaceutical and/or device companies across 918 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Marks is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Home visit, established patient, moderate complexity | 995 | $91 | $450 |
| Office visit, established patient (30-39 min) | 710 | $82 | $286 |
| Residence visit for established patient with high level of medical decision making, per day, if using time, at least 60 minutes | 608 | $131 | $639 |
| Blood glucose (sugar) test performed by hand-held instrument | 505 | $3 | $15 |
| Home visit, established patient, low complexity | 401 | $51 | $296 |
| Test to determine lung volumes using sensors | 350 | $38 | $127 |
| Test to examine how well the lungs exchange gases | 348 | $40 | $132 |
| Test to measure expiratory airflow and volume | 267 | $19 | $65 |
| New patient office visit (45-59 min) | 136 | $120 | $392 |
| Residence visit for new patient with high level of medical decision making, per day, if using time, at least 75 minutes | 123 | $138 | $756 |
| Transitional care management services for problem of high complexity | 102 | $210 | $998 |
| Urinalysis, manual | 95 | $3 | $15 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 88 | $26 | $96 |
| Residence visit for new patient with moderate level of medical decision making, per day, if using time, at least 60 minutes | 73 | $101 | $620 |
| Influenza vaccine, quadrivalent, 0.5 ml dosage | 48 | $20 | $75 |
| Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19) | 47 | $41 | $350 |
| Residence visit for established patient with straightforward medical decision making, per day, if using time, at least 15 minutes | 41 | $33 | $194 |
| Test for exercise-induced lung stress | 26 | $26 | $81 |
| Injection, ketorolac tromethamine, per 15 mg | 21 | $0 | $52 |
| Psychiatric diagnostic evaluation with medical services | 20 | $151 | $600 |
| Telephone or internet assessment with verbal and written report by consulting physician, more than 30 minutes | 20 | $52 | $140 |
| Transitional care management services for problem of at least moderate complexity | 20 | $153 | $660 |
| Telephone or internet assessment with verbal and written report by consulting physician, 21-30 minutes | 18 | $41 | $106 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 13 | $48 | $71 |
| Dexamethasone injection (steroid) | 13 | $0 | $5 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (97%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in pulmonary disease and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 1% for pulmonary disease in TX.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Marks is a clinical cardiology specialist, with above-average Medicare volume (top 4% in TX), and high industry engagement (speaking/promotional, top 1%), with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Marks experienced with home visit, established patient, moderate complexity?
Does Dr. Marks receive payments from pharmaceutical companies?
How do Dr. Marks's costs compare to other pulmonary diseases in San Antonio?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology